Evidence map›Paper›PMID 35287547›Full record

ArticleBioengineered2022

MicroRNA-3200-3p targeting CAMK2A modulates the proliferation and metastasis of glioma

Haibin Wang, Zhaobin Zeng, Renhui Yi, Jun Luo, Jinming Chen, Jianyun Lou

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Haibin WangDepartment of Neurosurgery, The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi, China.
Zhaobin ZengDepartment of Neurosurgery, The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi, China.
Renhui YiDepartment of Neurosurgery, The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi, China.
Jun LuoDepartment of Neurosurgery, The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi, China.
Jinming ChenDepartment of Neurosurgery, The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi, China.
Jianyun LouDepartment of Neurosurgery, The First Affiliated Hospital of Gannan Medical College, Ganzhou, Jiangxi, China.ORCID 0000-0001-9427-2565
First Affiliated Hospital of Gannan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNA (miRNA) is strongly interrelated with the pathogenesis of glioma. However, its potential biological effect and underlying mechanism of miR-3200-3p in human glioma remain elusive. In the current study, we checked the level of miR-3200-3p in different glioma cells. Then, its biological functions on glioma cell proliferation metastasis was investigated using the miR-3200-3p mimic and inhibitor. The direct target of miR-3200-3p was tested in these cells. Results demonstrated that miR-3200-3p is remarkably downregulated in human glioma cells. The relative level of miR-3200-3p is strongly associated with biological features, including proliferation, colony formation, and metastasis. Additionally, Ca

Indexed as

GliomaCalcium-Calmodulin-Dependent Protein Kinase Type 2Cell Line, TumorCell ProliferationHumansMAP Kinase Signaling SystemMicroRNAsCalcium-Calmodulin-Dependent Protein Kinase Type 2CAMK2A protein, humanMicroRNAsMIRN3200 microRNA, humanCAMK2AGliomametastasismiR-3200-3pproliferation

Identifiers

PMID35287547
PMCPMC9208524
OpenAlexW4220934413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.